Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 9, 2014, Pages 1363-1368

  Mawad, Raya ^a,b   Gooley, Ted A ^a   Rajendran, Joseph G ^c   Fisher, Darrell R ^d   Gopal, Ajay K ^a,b   Shields, Andrew T ^c   Sandmaier, Brenda M ^a,b   Sorror, Mohamed L ^a,b   Deeg, Hans Joachim ^a,b   Storb, Rainer ^a,b   Green, Damian J ^a,b   Maloney, David G ^a,b   Appelbaum, Frederick R ^a,b   Press, Oliver W ^a,b   Pagel, John M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Dade Moeller Associates   (United States)

Author keywords

Acute myeloid leukemia; Anti CD45 antibody; Hematopoietic cell transplantation; Iodine 131; Myelodysplastic syndrome; Radioimmunotherapy

Indexed keywords

BC8 AB I 131; CYCLOSPORIN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; DOSIMETRY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; ISOTOPE LABELING; MALE; MAXIMUM TOLERATED DOSE; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; RADIATION DOSE; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REMISSION; SURVIVAL RATE; WHOLE BODY RADIATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROCEDURES; RADIOIMMUNOTHERAPY; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84906100925     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.05.014     Document Type: Article

References (39)

1. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990, 76:1867-1871.
2. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991, 77:1660-1665.
3. Matthews D.C., Appelbaum F.R., Eary J.F., et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999, 94:1237-1247.
4. Pagel J., Gooley T., Rajendran J., et al. Targeted radiotherapy using 131I-anti-CD45 antibody followed by allogeneic hematopoietic cell transplantation (HCT): the relationships among dosimetry, bone marrow uptake, and relapse. Eur J Nucl Med Mol Imaging 2006, 33(Supp 2):S193.
5. Pagel J.M., Appelbaum F.R., Eary J.F., et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006, 107:2184-2191.
6. Andres T.L., Kadin M.E. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol 1983, 79:546-552.
7. Omary M.B., Trowbridge I.S., Battifora H.A. Human homologue of murine T200 glycoprotein. JExp Med 1980, 152:842-852.
8. Press O.W., Howell-Clark J., Anderson S., Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994, 83:1390-1397.
9. van der Jagt R.H., Badger C.C., Appelbaum F.R., et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res 1992, 52:89-94.
10. Taetle R., Ostergaard H., Smedsrud M., Trowbridge I. Regulation of CD45 expression in human leukemia cells. Leukemia 1991, 5:309-314.
11. Scheinberg D.A., Lovett D., Divgi C.R., et al. Aphase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. JClin Oncol 1991, 9:478-490.
12. Appelbaum F., Matthews D., Eary J.F., et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992, 54:829-833.
13. Schwartz M.A., Lovett D.R., Redner A., et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. JClin Oncol 1993, 11:294-303.
14. Pagel J.M., Gooley T.A., Rajendran J., et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009, 114:5444-5453.
15. Petersdorf E.W., Anasetti C., Martin P.J., et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 2004, 104:2976-2980.
16. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
17. Eary J.F., Press O.W., Badger C.C., et al. Imaging and treatment of B-cell lymphoma. JNucl Med 1990, 31:1257-1268.
18. Siegel J.A., Wessels B.W, Watson E.E., et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990, 3:213.
19. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. JNucl Med 1993, 34:689-694.
20. Fisher D.R., Badger C.C., Brietz H., et al. Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies. Antibody Immunoconj Radiopharm 1991, 4:655.
21. Tay J., Tinmouth A., Fergusson D., et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:206-217.
22. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. JClin Oncol 1988, 6:1562-1568.
23. Storer B.E. Small-sample confidence sets for the MTD in a phase I clinical trial. Biometrics 1993, 49:1117-1125.
24. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
25. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conferenceon Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
26. Martin P.J., McDonald G.B., Sanders J.E., et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004, 10:320-327.
27. Knopse W.H., Blom J., Crosby W.H. Regeneration of locally irradiated bone marrow: I. dose dependent, and stromal reaction, long-term changes in the rat, with particular emphasis upon vascular and stromal reaction. Blood 1966, 28:398-415.
28. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. JClin Oncol 2007, 25:4246-4254.
29. Pagel J.M. Radioimmunotherapeutic approaches for leukemia: the past, present and future. Cytotherapy 2008, 10:13-20.
30. Orozco J.J., Zeller J., Pagel J.M. Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome. Ther Adv Hematol 2012, 3:5-16.
31. Jurcic J. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia. JClin Oncol 2000, 19:8a. [Abstract].
32. Nemecek E.R., Hamlin D.K., Fisher D.R., et al. Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model. Clin Cancer Res 2005, 11:787-794.
33. Glatting G., Müller M., Koop B., et al. Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. JNucl Med 2006, 47:1335-1341.
34. Sandmaier B.M., Bethge W.A., Wilbur D.S., et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002, 100:318-326.
35. Kornblit B., Chen Y., Sandmaier B.M. Conditioning with alpha-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation. Chimerism 2012, 3:40-42.
36. Chen Y., Kornblit B., Hamlin D.K., et al. Durable donor engraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 2012, 119:1130-1138.
37. Pagel J.M., Hedin N., Drouet L., et al. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood 2008, 111:2261-2268.
38. Pagel J.M., Matthews D.C., Kenoyer A., et al. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. Cancer Res 2009, 69:185-192.
39. Pagel J.M., Kenoyer A.L., Bäck T., et al. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood 2011, 118:703-711.